PMID- 29325034
OWN - NLM
STAT- MEDLINE
DCOM- 20181127
LR  - 20181127
IS  - 1945-7170 (Electronic)
IS  - 0013-7227 (Linking)
VI  - 159
IP  - 4
DP  - 2018 Apr 1
TI  - Ghrelin Preserves Ischemia-Induced Vasodilation of Male Rat Coronary Vessels 
      Following beta-Adrenergic Receptor Blockade.
PG  - 1763-1773
LID - 10.1210/en.2017-03070 [doi]
AB  - Acute myocardial infarction (MI) triggers an adverse increase in cardiac 
      sympathetic nerve activity (SNA). Whereas beta-adrenergic receptor (beta-AR) blockers 
      are routinely used for the management of MI, they may also counter beta-AR-mediated 
      vasodilation of coronary vessels. We have reported that ghrelin prevents 
      sympathetic activation following MI. Whether ghrelin modulates coronary vascular 
      tone following MI, either through the modulation of SNA or directly as a 
      vasoactive mediator, has never been addressed. We used synchrotron 
      microangiography to image coronary perfusion and vessel internal diameter (ID) in 
      anesthetized Sprague-Dawley rats, before and then again 30 minutes after 
      induction of an MI (left coronary artery ligation). Rats were injected with 
      either saline or ghrelin (150 microg/kg, subcutaneously), immediately following the 
      MI or sham surgery. Coronary angiograms were also recorded following beta-AR 
      blockade (propranolol, 2 mg/kg, intravenously). Finally, wire myography was used 
      to assess the effect of ghrelin on vascular tone in isolated human internal 
      mammary arteries (IMAs). Acute MI enhanced coronary perfusion to 
      nonischemicregions through dilation of small arterioles (ID 50 to 250 microm) and 
      microvessel recruitment, irrespective of ghrelin treatment. In ghrelin-treated 
      rats, beta-AR blockade did not alter the ischemia-induced vasodilation, yet in 
      saline-treated rats, beta-AR blockade abolished the vasodilation of small 
      arterioles. Finally, ghrelin caused a dose-dependent vasodilation of IMA rings 
      (preconstricted with phenylephrine). In summary, this study highlights ghrelin as 
      a promising adjunct therapy that can be used in combination with routine beta-AR 
      blockade treatment for preserving coronary blood flow and cardiac performance in 
      patients who suffer an acute MI.
FAU - Pearson, James T
AU  - Pearson JT
AD  - Department of Cardiac Physiology, National Cerebral and Cardiovascular Center 
      Research Institute, Suita, Osaka, Japan.
FAU - Collie, Nicola
AU  - Collie N
AD  - Department of Physiology, School of Biomedical Sciences, HeartOtago University of 
      Otago, Dunedin, New Zealand.
FAU - Lamberts, Regis R
AU  - Lamberts RR
AD  - Department of Physiology, School of Biomedical Sciences, HeartOtago University of 
      Otago, Dunedin, New Zealand.
FAU - Inagaki, Tadakatsu
AU  - Inagaki T
AD  - Department of Vascular Physiology, National Cerebral and Cardiovascular Center 
      Research Institute, Suita, Osaka, Japan.
FAU - Yoshimoto, Misa
AU  - Yoshimoto M
AD  - Department of Health Sciences, Nara Women's University, Nara, Japan.
FAU - Umetani, Keiji
AU  - Umetani K
AD  - Japan Synchrotron Radiation Research Institute, Hyogo, Japan.
FAU - Davis, Philip
AU  - Davis P
AD  - Department of Cardiothoracic Surgery, HeartOtago, University of Otago, Dunedin, 
      New Zealand.
FAU - Wilkins, Gerard
AU  - Wilkins G
AD  - Department of Medicine Surgery, HeartOtago, University of Otago, Dunedin, New 
      Zealand.
FAU - Jones, Pete P
AU  - Jones PP
AD  - Department of Physiology, School of Biomedical Sciences, HeartOtago University of 
      Otago, Dunedin, New Zealand.
FAU - Shirai, Mikiyasu
AU  - Shirai M
AD  - Department of Advanced Medical Research for Pulmonary Hypertension, National 
      Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan.
FAU - Schwenke, Daryl O
AU  - Schwenke DO
AD  - Department of Physiology, School of Biomedical Sciences, HeartOtago University of 
      Otago, Dunedin, New Zealand.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Endocrinology
JT  - Endocrinology
JID - 0375040
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Ghrelin)
RN  - 0 (Vasodilator Agents)
RN  - 9Y8NXQ24VQ (Propranolol)
SB  - IM
MH  - Adrenergic beta-Antagonists/*pharmacology
MH  - Animals
MH  - Coronary Vessels/*drug effects/physiopathology
MH  - Ghrelin/*pharmacology
MH  - Heart Rate/drug effects
MH  - Male
MH  - Myocardial Infarction/physiopathology
MH  - Myocardial Ischemia/*physiopathology
MH  - Propranolol/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sympathetic Nervous System/drug effects
MH  - Vasodilation/*drug effects
MH  - Vasodilator Agents/*pharmacology
EDAT- 2018/01/13 06:00
MHDA- 2018/11/28 06:00
CRDT- 2018/01/12 06:00
PHST- 2017/10/26 00:00 [received]
PHST- 2017/12/20 00:00 [accepted]
PHST- 2018/01/13 06:00 [pubmed]
PHST- 2018/11/28 06:00 [medline]
PHST- 2018/01/12 06:00 [entrez]
AID - 4794851 [pii]
AID - 10.1210/en.2017-03070 [doi]
PST - ppublish
SO  - Endocrinology. 2018 Apr 1;159(4):1763-1773. doi: 10.1210/en.2017-03070.